Skip to main content
event logo
 

Bringing Chemistry to Medicine Symposium

 
Thursday, July 21, 2022: Transcription Therapy
Friday, July 22, 2022: Frontiers in Chemical Biology

 
 

The 3rd annual Bringing Chemistry to Medicine symposium featured talks by leading experts from around the globe working at the interface of chemical and biomedical sciences. Speakers represented expertise across a spectrum of research areas, including therapeutic regulation of transcription and chromatin, computational biology, and chemical biology. The event spanned two days with focused themes:

  • Thursday, July 21: Transcription Therapy
  • Friday, July 22: Frontiers in Chemical Biology

This symposium, hosted by the St. Jude Department of Chemical Biology and Therapeutics and the St. Jude Comprehensive Cancer Center, was a component of the institution’s strategic objective to establish a global hub focused on the emerging field of transcription-targeted therapeutics.

To enable broad participation and interaction among trainees and scientists around the world, registration was free.

 
 

Speakers

 
 

July 21, 2022

 
image of Scott Armstrong

Scott Armstrong, MD, PhD
Dana-Farber Cancer Institute

 
photo of Bradley Bernstein

Bradley Bernstein, MD, PhD
Dana Farber Cancer Institute

 
photo of Clifford Brangwynne

Clifford Brangwynne, PhD
Princeton University

 
photo of Jolanta Grembecka

Jolanta Grembecka, PhD 
University of Michigan

 
photo of Tanja Mittag

Tanja Mittag, PhD
St. Jude Children's Research Hospital

 
photo of Geeta Narlikar

Geeta Narlikar, PhD
University of California, San Francisco

 
photo of Fraydoon Rastinejad

Fraydoon Rastinejad, PhD
University of Oxford

 
photo of Ken Zaret

Ken Zaret, PhD
University of Pennsylvania

 

July 22, 2022

 
photo of Daniel Blair

Daniel Blair, PhD
University of Illinois at Urbana-Champaign

 
photo of Ray Deshaies

Ray Deshaies, PhD
Amgen, Inc.

 
photo of Matt Disney

Matt Disney, PhD
Scripps Research Institute (Florida)

 
photo of Ron Dror

Ron Dror, PhD
Stanford University

 
photo of Dorothee Kern

Dorothee Kern, PhD
Brandeis University

 
photo of Judith Klinman

Judith Klinman, PhD
University of California, Berkeley

 
photo of David Moore

David Moore, PhD
University of California, Berkeley

 
photo of Peter Schultz

Peter Schultz, PhD
Scripps Research Institute (La Jolla)

 
photo of Derek Tan

Derek Tan, PhD
Memorial Sloan Kettering Cancer Center

 
 

Agenda

 

Transcription Therapy
Thursday, July 21

Time (CDT) Event
9:00 - 9:15 am Opening Remarks
9:15 - 9:55 am Visualizing Drug-Binding Pockets in Transcription Factors
Fraydoon Rastinejad, PhD
University of Oxford

9:55 - 10:35 am Etiology and Impact of Methylation Changes in Cancer
Bradley Bernstein, MD, PhD
Dana-Farber Cancer Institute
10:35 - 10:45 am BREAK
10:45 - 11:25 am Overcoming Chromatin Barriers to Change Cell Fate
Ken Zaret, PhD
University of Pennsylvania
11:25 am - 12:05 pm Mechanism of the INO80 ATP-Dependent Chromatin Remodeling Machine
Geeta Narlikar, PhD
University of California, San Francisco

12:05 - 1:15 pm LUNCH
1:15 - 1:55 pm Intracellular Phase Transitions: The Fluidity of Biological Function
Clifford Brangwynne, PhD
Princeton University
1:55 - 2:35 pm Transcriptional Hubs or Condensates?
Tanja Mittag, PhD
St. Jude Children's Research Hospital

2:35 - 2:45 pm BREAK
2:45 - 3:25 pm Therapeutic Targeting of Epigenetic Modifiers in Leukemia
Jolanta Grembecka, PhD
University of Michigan

3:25 - 4:05 pm Therapeutic Targeting of Chromatin Complexes in Cancer
Scott Armstrong, MD, PhD
Dana-Farber Cancer Institute
4:05 - 4:35 pm
Discussion
4:35 - 4:45 pm Closing Remarks
 
 

Frontiers in Chemical Biology
Friday, July 22

Time (CDT) Events
9:00 - 9:10 am
Opening Remarks
9:10 - 9:50 am A Chemist’s Foray into Translational Research
Peter Schultz, PhD
Scripps Research Institute (La Jolla)
9:50 - 10:25 am SEAKERS: Targeted Cellular Micropharmacies that Generate Small-Molecule Drugs in situ
Derek Tan, PhD
Memorial Sloan Kettering Cancer Center
10:25 - 10:40 am BREAK
10:40 - 11:15 am Molecular Simulation and Machine Learning for the Design of Finely Tuned Drugs
Ron Dror, PhD
Stanford University

11:15 - 11:50 am
Integrating Protein Dynamics into Enzyme Function
Judith Klinman, PhD
University of California, Berkeley

12:00 - 1:00 pm LUNCH
1:00 - 1:35 pm Sequence-Based Design of Small Molecules Targeting RNA Structures to Manipulate and Study Disease Biology
Matt Disney, PhD
Scripps Research Institute (Florida)
1:35 - 2:10 pm Regulation of Liver Energy Balance by Nutrient-sensing Nuclear Receptors
David Moore, PhD
University of California, Berkeley
2:10 - 2:45 pm
Protein Dynamics at the Heart of New Cancer Drug Design Approaches
Dorothee Kern, PhD
Brandeis University
2:45 - 3:00 pm BREAK
3:00 - 3:35 pm The Awesome Power of Synthetic Organic Chemistry in Drug Development
Ray Deshaies, PhD
Institution
3:35 - 4:10 pm Modularized Molecule Making
Daniel Blair, PhD
University of Illinois at Urbana-Champaign
4:10 - 4:40 pm Discussion
4:40 - 4:45 pm Closing Remarks
 
 

Watch our Archived Lectures

In 2020 and 2021, St. Jude hosted exciting two-day events focused on Transcription Therapy and Chemical Biology and Therapeutics.

Visit our video archive link

Transcription Therapy at St. Jude

Over decades of research, scientists in the St. Jude Comprehensive Cancer Center and others have discovered that several pediatric cancers emerge due to disruption in chromatin and epigenetic states and dysfunctional transcriptional regulation. While gene regulation in general has long been considered “undruggable,” scientists in the St. Jude Department of Chemical Biology & Therapeutics (CBT) have created synthetic gene regulators and are devising new chemical approaches to inhibit or degrade malfunctioning components of chromatin and gene regulatory machineries. This work builds on the history of St. Jude as a pioneer in the therapeutic use of small molecules targeting gene regulation, most notably the application of glucocorticoid receptor agonists into chemotherapy regimens for pediatric patients with acute lymphoblastic lymphoma (ALL). The drugging of this transcription factor helped to dramatically increase overall survival rates for newly diagnosed ALL to 94% at St. Jude.

Learn more about transcription therapy at St. Jude    Learn more

 
 
Close